PETA: ‘Animals for disease research is like marketing carrier pigeons for mass communications’

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/mkirarslan)
(Image: Getty/mkirarslan)

Related tags: Contract research organization, In vitro, People for the ethical treatment of animals

The People for the Ethical Treatment of Animals (PETA) is looking to send a researcher to learn about non-animal test methods – adoption of which it says is slowed by regulatory agency acceptance.

The PETA International Science Consortium Ltd. is holding a contest to send an early career scientist to the annual Institute for In Vitro Sciences' (IIVS) Practical Methods for In Vitro Toxicology Workshop in January.

Dr. Amy Clippinger, PhD, associate director of the consortium and director of the PETA US Regulatory Testing Department told us IIVS will present on “numerous methods that can be used today to replace tests on animals​.”

Non-animal test methods for many toxicology endpoints—such as phototoxicity, skin and eye irritation/corrosion, and skin sensitization—already exist and additional methods for these and other endpoints are continuing to be developed, optimized, and incorporated into OECD​ test guidelines​,” said Clippinger.

Often, the bottleneck is not the science but the acceptance of new methods by regulatory agencies​,” she added.

To gain global regulatory acceptance, the consortium works with companies and regulatory agencies​ to gain acceptance of the new methods, explained Clippinger.

PETA at Biotech Week Boston

Last week, PETA protested outside a conference in Boston​, claiming Charles River Laboratories – sponsor of the inaugural World Congress on Animal Models in Drug Discovery & Development – “intentionally poisons animals​.”

The conference, which was part of Biotech Week Boston, centered around how innovative animal models, as well as in vitro​ and ex vivo​ modeling methods are shaping the future drug discovery.

Pushing the use of animals for disease research is like marketing carrier pigeons for mass communications – it wouldn’t work and it’s cruel​,” Kathy Guillermo, PETA senior vice president told us.

The majority of animal studies don’t lead to therapies for humans​,” she contested.

In response to the comments, Charles River told us the company has a deep commitment to animal welfare and makes every effort to exceed national standards for the care of the research models.

The survival rates for major diseases are at an all-time high thanks to the discovery of new drugs​,” contract research organization (CRO) said in the comment. “Our work is an essential component of the research that has led to these discoveries and is required by the FDA. Charles River has played a vital role in virtually every medical advance for humans as well as animals​.”

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 01-Jun-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

Related suppliers

Follow us

Products

View more

Webinars